NCT06426953 Predictive Effect of TGF-β and INS-PI3K-AKT Related Proteins for POD in Diabetes Patients
| NCT ID | NCT06426953 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xie Kangjie |
| Condition | Diabetes |
| Study Type | OBSERVATIONAL |
| Enrollment | 180 participants |
| Start Date | 2024-05-20 |
| Primary Completion | 2025-12-30 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
To investigate the relationship between POD, TGF-β and INS-PI3K-AKT signaling pathway related proteins (ADNP, MAP6, PGC-1α) in diabetic patients
Eligibility Criteria
Inclusion Criteria: 1. Age ≥65 years 2. History of diabetes ≥2 years and Glycated hemoglobin ≥6.5% or no history of diabetes and normal blood glucose 3. The ASA rating is Class I to III 4. The elderly patients of limited thoracic and abdominal tumor surgery Exclusion Criteria: 1. Refused to participate 2. Previous history of schizophrenia, epilepsy, Parkinson's disease 3. History of alcohol abuse or drug dependence 4. Patients with ASA grade IV and above 5. Severe visual or hearing impairment, can not cooperate with the completion of cognitive function tests 6. Participants in other clinical trials within the last two months 7. Patients with severe arrhythmia or cardiac dysfunction(EF\<40%) 8. There was a clear history of neurological and psychiatric problems or long-term use of sedatives or antidepressants 9. History of cerebrovascular disease or brain surgery or trauma 10. Severe liver dysfunction (Child-Pugh class C) or severe renal dysfunction (requiring dialysis)
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.